News
- Author:
- Neil Osterweil
Publish date: July 11, 2018
STOCKHOLM – An ongoing study shows a high clinical response rate and acceptable safety profile with the chemotherapy-free targeted therapy combinat...
News
- Author:
- Neil Osterweil
Publish date: July 10, 2018
The LILAC trial comparing ABP 980 to trastuzumab missed its primary endpoint, but the biosimilar outperformed the reference drug in efficacy.
News
- Author:
- Neil Osterweil
Publish date: July 10, 2018
The oral formulation offers a convenient alternative for treating non–high-risk acute promyelocytic leukemia.
News
- Author:
- Neil Osterweil
Publish date: July 9, 2018
STOCKHOLM – The combination of the BCL2 inhibitor and attenuated dose chemotherapy showed good early efficacy in a dose-expansion study.
News
- Author:
- Neil Osterweil
Publish date: July 6, 2018
Circulating tumor cells expressing prostate-specific membrane antigen could be a patient-selection marker.
News
- Author:
- Neil Osterweil
Publish date: July 5, 2018
Neuropilin-1 was a more sensitive and specific marker for HCC than alpha fetoprotein, the current standard.
News
- Author:
- Neil Osterweil
Publish date: July 5, 2018
STOCKHOLM – A hospital-based dose-escalation protocol got CLL patients up to the target dose of venetoclax in 12 days, versus 35 days with the labe...
News
- Author:
- Neil Osterweil
Publish date: July 2, 2018
STOCKHOLM – Idarubicin and vancomycin were associated with increased liver toxicities in adults with ALL receiving PEG-ASP, but other agents were n...
News
- Author:
- Neil Osterweil
Publish date: June 29, 2018
MicroRNAs are associated with elevated liver enzymes and fibrosis in HIV, HCV infection.
News
- Author:
- Neil Osterweil
Publish date: June 25, 2018
BARCELONA – Five patients with intrahepatic cholangiocarcinomas or gallbladder tumors had partial but durable responses in a phase 2 trial.
News
- Author:
- Neil Osterweil
Publish date: June 22, 2018
The oral thymidine analogue/thymidine phosphorylase inhibitor was associated with a 2.1 month overall survival benefit in heavily pretreated patien...
News
- Author:
- Neil Osterweil
Publish date: June 21, 2018
BARCELONA – The immune checkpoint inhibitor was not statistically superior to paclitaxel, but trends point to better outcomes with pembrolizumab, i...
News
- Author:
- Neil Osterweil
Publish date: June 21, 2018
BARCELONA – A pooled analysis of two phase 3 trials showed a 3-month overall survival benefit in patients with alpha-fetoprotein levels of 400 ng/m...
News
- Author:
- Neil Osterweil
Publish date: June 20, 2018
STOCKHOLM – The compound CAR T simultaneously targeted antigens in bulky disease and on leukemic stem cells in acute myeloid leukemia.
News
- Author:
- Neil Osterweil
Publish date: June 17, 2018
STOCKHOLM, SWEDEN – A novel CAR T construct was effective for children with ALL in relapse after CD19-directed CAR T therapy.
